A novel combination: Ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1871-1879

  Ramos Nino, Maria E ^a   Littenberg, Benjamin ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANPIRNASE; ROSIGLITAZONE; SURVIVIN; TRANSCRIPTION FACTOR FRA 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN C FOS; RIBONUCLEASE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; THIAZOLIDINEDIONES;

EID: 51049098981     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0308     Document Type: Article

References (30)

1. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 2001;7:2213-21.
2. Chiappetta G, Ferraro A, Botti G, et al. FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 2007;7:17.
3. Zajchowski D, Bartholdi M, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
4. Chiappetta G, Tallini G, De Biasio MC, et al. FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clin Cancer Res 2000;6:4300-6.
5. Casalino L, Bakiri L, Talotta F, et al. Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J 2007;26:1878-90.
6. Kustikova O, Kramerov D, Grigorian M, et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998;18:7095-105.
7. Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res 2007;67:6204-11.
8. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002;62:6065-9.
9. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-9.
10. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
11. Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Veterinary Pathol 2004;41:599-607.
12. Ramos-Nino M. Cytotoxic ribonuclease-based cancer therapies. Drugs Future 2007;32:517-26.
13. Halicka HD, Murakami T, Papageorgio CN, et al. Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. Cell Prolif 2000;33:407-17.
14. Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K. Tumoricidal effects of onconase on various tumors. J Surg Oncol 2000;73:164-71.
15. Darzynkiewicz Z, Carter M, Mikulski S, Ardelt W, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988;21:169-82.
16. Rybak SM, Pearson JW, Fogler WE, et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst 1996;88:747-53.
17. Juan G, Ardelt B, Li X, et al. G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF/CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia 1998;8:1241-8.
18. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 2001;97:528-35.
19. Ramos-Nino ME, Vianale G, Sabo-Attwood T, et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005;4:835-42.
20. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990;82:151-3.
21. Nunez M, Martin G, Cocca C, et al. Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat. Anticancer Res 2006;26:2113-22.
22. Russu WA. Thiazolidinedione anti-cancer activity: is inhibition of microtubule assembly implicated? Med Hypotheses 2007;68:343-6.
23. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, et al. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 2008;38:209-17.
24. Kawamura K, Fukuda J, Shimizu Y, Kodama H, Tanaka T. Survivin contributes to the anti-apoptotic activities of transforming growth factor alpha in mouse blastocysts through phosphatidylinositol 3′-kinase pathway. Biol Reprod 2005;73:1094-101.
25. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, et al. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 2008;38:209-17.
26. BeruBe K, Quinlan T, Fung H, et al. Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. Am J Respir Cell Mol Biol 1996;15:141-7.
27. Scapoli L, Ramos-Nino ME, Martinelli M, Mossman BT. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene 2004;23:805-13.
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
29. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-9.
30. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARg-independent signal pathways. Mol Cancer Ther 2006;5:430-7.